reports
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biot...
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET. The fireside chats will be webcast live and may be accessed through Relay Therapeutics’ website under Eve...
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy ...
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY),...
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (...
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mas...
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Co...
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates Continued focused execution of RLY-2608 clinical trials in PI3Kα-mutated breast cancer and vascular malformations Appointed Lonnel Coats and Habib Dable, former biotech CEOs with launch and commercialization expertise, to the Company’s Board of Directors Approximately $596 million in cash, cash equivalents and investments at end of Q3 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changin...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in November: Guggenheim’s 2nd Annual Healthcare Innovation Conference on Monday, November 10, 2025 at 11:00-11:25 a.m. ETJefferies 2025 Global Healthcare Conference on Wednesday, November 19, 2025 at 11...
Relay Therapeutics to Announce Third Quarter 2025 Financial Results an...
Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, November 6, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicin...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
XENE XENON PHARMACEUTICALS INC
SEDG SOLAREDGE TECHNOLOGIES INC.
RUN SUNRUN INC.
LTRX LANTRONIX INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
LAKE LAKELAND INDUSTRIES INC.
CEVA CEVA INC.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ALB ALBEMARLE CORPORATION
EFR ENERGY FUELS
RELL RICHARDSON ELECTRONICS LTD.
NTLA INTELLIA THERAPEUTICS INC.
UAMY UNITED STATES ANTIMONY CORP.
BOMN BOSTON OMAHA
ICL ICL GROUP LTD.
LWLG LIGHTWAVE LOGIC
IMTX IMMATICS N V (A)
ARRY ARRAY TECHNOLOGIES
IMVT IMMUNOVANT
RLAY RELAY THERAPEUTICS
FLUX FLUX POWER HOLDINGS
GLUE MONTE ROSA THERAPEUTICS INC
ASTS AST SPACEMOBILE INC
TRDA ENTRADA THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
APLD APPLIED BLOCKCHAIN INC
IE IVANHOE ELECTRIC INC
NUVL NUVALENT INC
COHR COHERENT CORP
CRML CLAL INDUSTRIES & BEVERAGES LTD
GPCR STRUCTURE THERAPEUTICS
OCS OCULIS HOLDING AG
LAES SEALSQ CORP
NB NIOCORP DEVELOPMENTS LTD.
METBV FORTREA HOLDINGS INC.
FTREV SAGIMET BIOSCIENCES INC
SGMT BYRNA TECHNOLOGIES INC
BYRN ENGENE HOLDINGS INC
ENGN SPYRE THERAPEUTICS INC.
SYRE NEUROGENE INC
NGNE RAMACO RESOURCES INC.
METC TOYO CO LTD
TOYO SERVE ROBOTICS INC
SERV UPSTREAM BIO INC
UPB CIDARA THERAPEUTICS INC.
CDTX AMERICAN BATTERY TECHNOLOGY COMPANY
ABAT TVARDI THERAPEUTICS INC
TVRD USA RARE EARTH INC
USAR HYCROFT MINING HOLDING CORPORATION
HYMC CATALYST PERINI STRATEGIC INCOM ORD
CSIOX CHARGEPOINT HOLDINGS INC.
CHPT KULR TECHNOLOGY GROUP INC.
KULR GRAFTECH INTERNATIONAL LTD.
EAF GLOBALSTAR INC.
GSAT INHIBRX BIOSCIENCES INC.
INBX KON TUM CONSTRUCTION MATERIALS ORD
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
SCHL SCHOLASTIC CORPORATION
MRCY MERCURY SYSTEMS INC.
LPTH LIGHTPATH TECHNOLOGIES INC. CL A
KURA KURA ONCOLOGY INC.
JACK JACK IN THE BOX INC.
INTC INTEL CORPORATION
HELE HELEN OF TROY LIMITED
CROX CROCS INC.
AIR AAR CORP.
UNFI UNITED NATURAL FOODS INC.
LINK INTERLINK ELECTRONICS
SRRK SCHOLAR ROCK HOLDING CORPORATION
STOK STOKE THERAPEUTICS
IMTX IMMATICS N V (A)
KYMR KYMERA THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
COGT COGENT BIOSCIENCES INC
RLAY RELAY THERAPEUTICS
HIMS HIMS AND HERS HEALTH INC (A)
VERA VERA THERAPEUTICS INC
TNGX TANGO THERAPEUTICS INC
DSGN DESIGN THERAPEUTICS INC
GLUE MONTE ROSA THERAPEUTICS INC
MBC_w MASTERBRAND INC
IRON DISC MEDICINE INC
CTNM CONTINEUM THERAPEUTICS INC
PACS PACS GROUP INC
ZBIO ZENAS BIOPHARMA INC.
UPB UPSTREAM BIO INC
MIR MIRION TECHNOLOGIES INC
SION SIONNA THERAPEUTICS INC
KLRS KALARIS THERAPEUTICS INC
BKTI BK TECHNOLOGIES CORP
EMPG EMPRO GROUP INC
Relay Therapeutics to Participate in Two Upcoming Investor Conferences...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in September: 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. ETMorgan Stanley 23rd Annual Global Conference on Wednesday, September 10, 2025 at 11:30 a.m. ET The fi...
Relay Therapeutics Reports Second Quarter 2025 Financial Results and C...
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates Presented updated data at ASCO showing consistency with prior data, including 10.3-month median PFS and 39% ORR in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Initiated Phase 3 ReDiscover-2 trial in Q2 Approximately $657 million in cash, cash equivalents and investments at end of Q2 2025 CAMBRIDGE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living ...
Relay Therapeutics to Announce Second Quarter 2025 Financial Results a...
Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report second quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 7, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transfor...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Direct...
Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors CAMBRIDGE, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced the appointment of Claire Mazumdar, Ph.D., to the Company’s Board of Directors, effective June 9, 2025. “It is a privilege to welcome Claire to our Board, where she will draw from her strategic and operational experience in clinical-stage oncology to offer guidance as we prepare ...
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant F...
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medi...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:45 a.m. ETGoldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025 at 2:40 p.m. ET The fireside chats will be webcast...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: BoA Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 3:40 p.m. PTTD Cowen’s 6th Annual Oncology Innovation Summit on Tuesday, May 27, 2025 at 3:30 p.m. ET The fireside chats will be webcast live and ...
Relay Therapeutics Reports First Quarter 2025 Financial Results and Co...
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a cl...
Relay Therapeutics to Announce First Quarter 2025 Financial Results an...
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025 CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the ...
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
NEOG NEOGEN CORPORATION
LAKE LAKELAND INDUSTRIES INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
ALOT ASTRONOVA INC.
IIFw MORGAN STANLEY INDIA INVESTMENT FUND INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PASG PASSAGE BIO
RLAY INC.
CTGO RELAY THERAPEUTICS
TEAF CONTANGO ORE INC.
PROK ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
MIO PROKIDNEY CORP.
DMA PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
ADVM DESTRA MULTI ALTERNATIVE FUND
GF ADVERUM BIOTECHNOLOGIES INC.
THE NEW GERMANY FUND
INC.
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial...
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 + fulvestrant showing 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib triplet, and planning for development of future oral endocrine the...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
Relay Therapeutics to Participate in Two Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats: TD Cowen’s 45th Annual Health Care Conference on Wednesday, March 5, 2025 at 1:50 p.m. ETBarclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 at 11:00 a.m. ET The fireside chats will be webcast...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.